Cardiovascular Contrast-enhanced Magnetic Resonance Imaging Using Polysaccharide Superparamagnetic Iron Oxide Injection in Diabetic Patients

NCT06051565 | Completed Phase 1

• 1 other identifier: DJTCSCYHT-I-03
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open-label, single-center, single-dose study aims to evaluate the effect and safety of polymeric superparamagnetic iron oxide in cardiovascular magnetic resonance imaging for diabetic patients with concomitant chronic kidney disease.

Conditions

Diabetes; Magnetic Resonance Imaging

Outcome Measures

Primary Outcomes (3)

• The number of vascular segments with lesions

  The number of vascular segments with lesions after administration

  0 hour after administration

• Lesion length

  Vascular lesion length

  0 hour after administration

• Degree of vascular stenosis

  Vascular stenosis degree

  0 hour after administration

Secondary Outcomes (9)

• Image quality scores

  0 hour after administration

• Myocardium T1 values

  0 hour after administration

• Signal-to-noise ratio

  0 hour after administration

• Contrast-to-noise ratio

  0 hour after administration

• Adverse event rate

  Baseline up to 24 hours after administration

Study Arms (1)

Polysaccharide superparamagnetic iron oxide injection

EXPERIMENTAL

Intravenous injected polysaccharide superparamagnetic iron oxide injection at 3 mg/kg dose

Drug: Polysaccharide superparamagnetic iron oxide injection

Interventions

Polysaccharide superparamagnetic iron oxide injection DRUG

Polysaccharide superparamagnetic iron oxide injection can be used for the treatment of iron-deficiency anemia and for magnetic resonance imaging enhancement.

Polysaccharide superparamagnetic iron oxide injection

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged ≥ 18 years, ≤ 80 years.
• Patients who have been diagnosed with chronic kidney disease (CKD) according to diagnostic criteria, meeting at least one CKD diagnostic criterion.
• Patients with a confirmed history of atherosclerosis and/or chronic venous disease (including deep vein thrombosis, thrombotic venous inflammation, lower limb varicose veins, etc.) either in their medical history or diagnosed during hospital admission, and within the past year, at least one imaging examination has confirmed the presence of at least one of the following vascular abnormalities in at least one vascular bed:
• ≥50% vascular stenosis;
• Arterial aneurysm;
• Arterial dissection;
• Arteriovenous malformation;
• Arteriovenous fistula;
• Vascular developmental abnormalities;
• Patients capable of self-care in daily life.
• Patients who voluntarily agree to participate in this study, sign an informed consent form, have a full understanding of the trial's content, procedures, and potential adverse reactions, and demonstrate good compliance.
• Patients who are unwilling to sign an informed consent form for the exploratory research can still be enrolled in the main study.
• Subjects who have no plans for pregnancy for at least 2 weeks before self-administration of the investigational drug and for at least 6 months after the last use of the investigational drug and voluntarily agree to adopt effective contraceptive measures.

You may not qualify if:

• Patients who have undergone stent implantation for vascular treatment in the target vascular bed.
• Patients who have had or currently have malignant tumors within the last 3 years.
• Serum ferritin \> 1000 μg/L.
• Patients who are planned to undergo magnetic resonance imaging (MRI) examination for various reasons during the trial.
• Blood donation or significant blood loss (\> 450 ml) within the two months before medication.
• Patients with a history of substance abuse involving psychotropic drugs and are unable to quit or have psychiatric disorders.
• Patients with any severe and/or uncontrolled diseases, including:
• Outpatients diagnosed through medical history; inpatients diagnosed based on past medical history and current medical history indicating ≥ Grade 2 myocardial ischemia or myocardial infarction, ≥ Grade 2 congestive heart failure (New York Heart Association (NYHA) classification).
• Active or uncontrolled severe systemic infections (≥ Common Terminology Criteria for Adverse Events (CTCAE) 5.0 Grade 2).
• Infectious diseases such as cirrhosis, active hepatitis\*, syphilis, human immunodeficiency virus (HIV), etc. \*Reference for hepatitis B: hepatitis B surface antigen (HBsAg) positive and Hepatitis B Virus (HBV) DNA test value exceeds the upper limit of normal; Reference for hepatitis C: Hepatitis C Virus (HCV) antibody positive and HCV viral titer test value exceeds the upper limit of normal.
• History of immunodeficiency, acquired or congenital immunodeficiency diseases, or organ transplantation.
• Pregnancy or currently breastfeeding or planning to breastfeed during the study.
• Presence of metal objects in the body (dentures, contraceptive rings, metal implants, metal clips, etc.) and claustrophobia.
• Allergic reactions to the investigational drug, its metabolites, or excipients.
• Use of the investigational drug or participation in drug clinical trials within the two months before medication.

Sponsors & Collaborators

• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.: lead

Study Sites (1)

Beijing Luhe Hospital, Capital Medical University

Beijing, Beijing Municipality, 101149, China

Location

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 18, 2023
• First Posted: September 25, 2023
• Study Start: November 6, 2021
• Primary Completion: June 13, 2022
• Study Completion: September 15, 2022
• Last Updated: September 29, 2023

Record last verified: 2021-10

Locations

CN (1)